A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease.

The main factors of Alzheimer's disease (AD) are the cerebral accumulation and the formation of extracellular amyloid plaques. The Aβ peptides are highly able to accumulative and produce fibrils that are placed to form these plaques in the AD. The biological action and drug delivery properties of curcumin (Cur) nanoformulation in the Alzheimer's disease therapeutics can be developed by the altering surface of the Poly-lactide-co-glycolide (PLGA) polymer and encapsulation of selenium nanoparticles (Se NPs). The morphological structure, size distributions of nanospheres, chemical interactions between the polymer and nanoformulations of synthesized curcumin and Se NPs loaded PLGA nanospheres have been studied by using the techniques of analytical instruments. The microscopic and nano observation results of synthesized Cur loaded nanospheres are exhibited that the mono-dispersed distributions of particles with spherical shaped structure. The present drug delivery system of Cur loaded Se-PLGA nanospheres could be decreases the amyloid-β load in the brains samples of AD mice, and greatly cured the memory deficiency of the model mice. The specific binding of Cur loaded Se-PLGA nanospheres with Aβ plaques were visualized by fluorescence microscopic technique. Se-PLGA targeting delivery system to amyloid plaques might be providing the enhanced therapeutic efficacy in AD lesions, which was studied by using transgenic mice (5XFAD). In conclusion, Cur loaded Se-PLGA nanoformulation has been demonstrated that valued delivery system for the targeted delivery and effective way to treat AD.